Tuesday, April 11, 2023

Amarillo Division

CONCLUSION

For the foregoing reasons, the Court GRANTS the Motion IN PART.  FDA's approval of mifepristone is hereby STAYED.  The Court STAYS the applicability of this opinion and order for seven (7) days to allow the federal government time to seek emergency relief from the United States Court of Appeals for the Fifth Circuit.

SO ORDERED.
April 7, 2023

-- US District Judge Matthew J. Kacsmaryk granting the plaintiffs motion for a stay in Alliance For Hippocratic Medicine, et al., v U.S. Food And Drug Administration, 7 April 2023

No comments: